GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Ipsen SA (OTCPK:IPSEF) » Definitions » 3-Year EPS without NRI Growth Rate

Ipsen (IPSEF) 3-Year EPS without NRI Growth Rate : 7.80% (As of Dec. 2023)


View and export this data going back to 2009. Start your Free Trial

What is Ipsen 3-Year EPS without NRI Growth Rate?

Ipsen's EPS without NRI for the six months ended in Dec. 2023 was $4.82.

During the past 12 months, Ipsen's average EPS without NRI Growth Rate was -12.90% per year. During the past 3 years, the average EPS without NRI Growth Rate was 7.80% per year. During the past 5 years, the average EPS without NRI Growth Rate was 11.20% per year. During the past 10 years, the average EPS without NRI Growth Rate was 35.80% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EPS without NRI growth rate.

During the past 13 years, the highest 3-Year average EPS without NRI Growth Rate of Ipsen was 495.40% per year. The lowest was -74.80% per year. And the median was 9.30% per year.

Competitive Comparison of Ipsen's 3-Year EPS without NRI Growth Rate

For the Drug Manufacturers - Specialty & Generic subindustry, Ipsen's 3-Year EPS without NRI Growth Rate, along with its competitors' market caps and 3-Year EPS without NRI Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Ipsen's 3-Year EPS without NRI Growth Rate Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Ipsen's 3-Year EPS without NRI Growth Rate distribution charts can be found below:

* The bar in red indicates where Ipsen's 3-Year EPS without NRI Growth Rate falls into.


Ipsen 3-Year EPS without NRI Growth Rate Calculation

This is the 3-year average growth rate of EPS without NRI. The growth rate is calculated using exponential compounding based on the latest four year annual data.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EPS without NRI growth rate.

Ipsen  (OTCPK:IPSEF) 3-Year EPS without NRI Growth Rate Explanation

EPS without NRI is the amount of earnings without non-recurring items per outstanding share of the company's stock.

Earnings Per Share (EPS) is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists Earnings per share without Non-Recurring Items, which better reflects the company's underlying performance.

Ipsen 3-Year EPS without NRI Growth Rate Related Terms

Thank you for viewing the detailed overview of Ipsen's 3-Year EPS without NRI Growth Rate provided by GuruFocus.com. Please click on the following links to see related term pages.

Ipsen (IPSEF) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Ipsen SA (OTCPK:IPSEF) » Definitions » 3-Year EPS without NRI Growth Rate
Comparable Companies
XPAR:VETO XPAR:BOI XPAR:EAPI XPAR:AB XPAR:MLCOT XPAR:ALRPD ZTS XTER:MRK NSE:SUNPHARMA TSE:4502 LSE:HLN XTAE:TEVA XSWX:SDZ VTRS SZSE:000538 NBIX HKSE:03692 TSE:4507 NSE:DIVISLAB BOM:500124
Traded in Other Exchanges
IPSEY:USA 0MH6:UK IPN:France I7G:Germany I7G:Germany
Address
65 Quai Georges Gorse, Billancourt Cedex, Boulogne, FRA, 92100
Website
https://www.ipsen.com
Ipsen is a global biotechnology company headquartered in France that develops and commercializes medicines across three therapeutic areas: oncology, neuroscience, and rare diseases. Ipsen was founded in 1929 as a consumer healthcare company focused on prescription-based products for digestive disorders and neurological disorders. Over the past nearly 100 years, Ipsen has shifted its focus to specialty care, which comprises the vast majority of its total revenue. In February 2022, Ipsen announced the divestment of its consumer healthcare business, which accounted for 8% of 2021 revenue. Ipsen has a large global footprint and sells more than 25 drugs in 115 countries.